• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Dis . Nature and dimensions of the systemic hyper-inflammation and its attenuation by convalescent plasma in severe COVID-19

tetano

Editor, Senior Moderator
J Infect Dis


. 2021 Jan 12;jiab010.
doi: 10.1093/infdis/jiab010. Online ahead of print.
Nature and dimensions of the systemic hyper-inflammation and its attenuation by convalescent plasma in severe COVID-19


Purbita Bandopadhyay[SUP] 1 [/SUP], Ranit D' Rozario[SUP] 1 [/SUP], Abhishake Lahiri[SUP] 2 [/SUP], Jafar Sarif[SUP] 1 [/SUP], Yogiraj Ray[SUP] 3 4 [/SUP], Shekhar Ranjan Paul[SUP] 3 [/SUP], Rammohan Roy[SUP] 3 [/SUP], Rajshekhar Maiti[SUP] 3 5 [/SUP], Kausik Chaudhuri[SUP] 3 [/SUP], Saugata Bagchi[SUP] 3 [/SUP], Ayan Maiti[SUP] 3 [/SUP], Md Masoom Perwez[SUP] 3 [/SUP], Biswanath Sharma Sarkar[SUP] 3 [/SUP], Devlina Roy[SUP] 3 [/SUP], Rahul Chakraborty[SUP] 3 [/SUP], Janani Srinivasa Vasudevan[SUP] 6 [/SUP], Sachin Sharma[SUP] 6 [/SUP], Durba Biswas[SUP] 7 [/SUP], Chikam Maiti[SUP] 7 [/SUP], Bibhuti Saha[SUP] 4 [/SUP], Prasun Bhattacharya[SUP] 7 [/SUP], Rajesh Pandey[SUP] 6 [/SUP], Shilpak Chatterjee[SUP] 1 [/SUP], Sandip Paul[SUP] 2 [/SUP], Dipyaman Ganguly[SUP] 1 [/SUP]



Affiliations

Abstract

Novel coronavirus SARS-CoV2, causing coronavirus disease 2019 or COVID-19, led to significant morbidity and mortality. While most suffer from mild symptoms, some patients progress to a severe disease with acute respiratory distress syndrome (ARDS) and an associated systemic hyper-inflammation. First to characterize key cytokines and their dynamics in this hyper-inflammatory condition, we assessed abundance and correlative expression of a panel of forty eight cytokines in patients progressing to ARDS, as compared to patients with mild disease. Then in an ongoing randomized control trial of convalescent plasma therapy (CPT), we analyzed rapid effects of CPT on the systemic cytokine dynamics, as a correlate for the level of hypoxia experienced by the patients. We identified an anti-inflammatory role of CPT independent of its neutralizing antibody content. Neutralizing antibodies as well as reductions in circulating interleukin-6 and interferon gamma induced protein 10, contributed to marked rapid reductions in hypoxia in response to CPT.

Keywords: Acute respiratory distress syndrome; COVID-19; Convalescent plasma; Cytokine; Hypoxia; SARS-CoV-2; hyper-inflammation.
 
Back
Top Bottom